Timing Cancer Treatment

Researchers led by members of the Department of Systems Biology at Harvard Medical School had been studying how silencing MDMX, an oncogene, affected the dynamics of p53, a natural tumor suppressor, in cancer cells when they realized those dynamics might affect the cells’ sensitivity to a second, chemotherapy-like treatment.

Learn more at https://hms.harvard.edu/news/timing-matters